The Union Forever: Lincoln, Grant, and the Civil War

A Prominent Historian’s Life’s Work Investigating Three Giants John Y. Simon was an exceptional scholar. As the founding editor of The Papers of Ulysses S. Grant in 1964, John presided over the project for forty years and thirty-one volumes, setting the gold standard for document...

The Defense of Berlin

Originally published in 1963. In 1958 Nikita Khrushchev demanded that the United States, Great Britain, and France withdraw from West Berlin. His demands eventually resulted in the division of Germany's capital city through the building of the Berlin Wall. In The Defense of Berlin, Jean Edward Smith discusses Berlin from the time of arrangements set during the war through 1962, with an emphasis on the effect that the crisis of division had on the city

Thirty Meter Telescope Narrow Field InfraRed Adaptive Optics System Real-Time Controller Prototyping Results

Prototyping and benchmarking was performed for the Real-Time Controller (RTC) of the Narrow Field InfraRed Adaptive Optics System (NFIRAOS). To perform wavefront correction, NFIRAOS utilizes two deformable mirrors (DM) and one tip/tilt stage (TTS). The RTC receives wavefront information from six Laser Guide Star (LGS) Shack- Hartmann WaveFront Sensors (WFS), one high-order Natural Guide Star Pyramid WaveFront Sensor (PWFS) and multiple low-order instrument detectors. The RTC uses this information to determine the commands to send to the wavefront correctors. NFIRAOS is the first light AO system for the Thirty Meter Telescope (TMT). The prototyping was performed using dual-socket high performance Linux servers with the real-time (PREEMPT_RT) patch and demonstrated the viability of a commercial off-the-shelf (COTS) hardware approach to large scale AO reconstruction. In particular, a large custom matrix vector multiplication (MVM) was benchmarked which met the required latency requirements. In addition all major inter-machine communication was verified to be adequate using 10Gb and 40Gb Ethernet. The results of this prototyping has enabled a CPU-based NFIRAOS RTC design to proceed with confidence and that COTS hardware can be used to meet the demanding performance requirements

Observing Extended Sources with the \Herschel SPIRE Fourier Transform Spectrometer

The Spectral and Photometric Imaging Receiver (SPIRE) on the European Space Agency's Herschel Space Observatory utilizes a pioneering design for its imaging spectrometer in the form of a Fourier Transform Spectrometer (FTS). The standard FTS data reduction and calibration schemes are aimed at objects with either a spatial extent much larger than the beam size or a source that can be approximated as a point source within the beam. However, when sources are of intermediate spatial extent, neither of these calibrations schemes is appropriate and both the spatial response of the instrument and the source's light profile must be taken into account and the coupling between them explicitly derived. To that end, we derive the necessary corrections using an observed spectrum of a fully extended source with the beam profile and the source's light profile taken into account. We apply the derived correction to several observations of planets and compare the corrected spectra with their spectral models to study the beam coupling efficiency of the instrument in the case of partially extended sources. We find that we can apply these correction factors for sources with angular sizes up to \theta_{D} ~ 17". We demonstrate how the angular size of an extended source can be estimated using the difference between the sub-spectra observed at the overlap bandwidth of the two frequency channels in the spectrometer, at 959<\nu<989 GHz. Using this technique on an observation of Saturn, we estimate a size of 17.2", which is 3% larger than its true size on the day of observation. Finally, we show the results of the correction applied on observations of a nearby galaxy, M82, and the compact core of a Galactic molecular cloud, Sgr B2.Comment: Accepted for publication by A&

1965 Ruby Yearbook

A digitized copy of the 1965 Ruby, the Ursinus College yearbook.https://digitalcommons.ursinus.edu/ruby/1068/thumbnail.jp

The fables of pity: Rousseau, Mandeville and the animal-fable

Copyright @ 2012 Edinburgh University PressPrompted by Derrida’s work on the animal-fable in eighteenth-century debates about political power, this article examines the role played by the fiction of the animal in thinking of pity as either a natural virtue (in Rousseau’s Second Discourse) or as a natural passion (in Mandeville’s The Fable of the Bees). The war of fables between Rousseau and Mandeville – and their hostile reception by Samuel Johnson and Adam Smith – reinforce that the animal-fable illustrates not so much the proper of man as the possibilities and limitations of a moral philosophy that is unable to address the political realities of the state

How COVID-19 has fundamentally changed clinical research in global health

COVID-19 has had negative repercussions on the entire global population. Despite there being a common goal that should have unified resources and efforts, there have been an overwhelmingly large number of clinical trials that have been registered that are of questionable methodological quality. As the final paper of this Series, we discuss how the medical research community has responded to COVID-19. We recognise the incredible pressure that this pandemic has put on researchers, regulators, and policy makers, all of whom were doing their best to move quickly but safely in a time of tremendous uncertainty. However, the research community\u27s response to the COVID-19 pandemic has prominently highlighted many fundamental issues that exist in clinical trial research under the current system and its incentive structures. The COVID-19 pandemic has not only re-emphasised the importance of well designed randomised clinical trials but also highlighted the need for large-scale clinical trials structured according to a master protocol in a coordinated and collaborative manner. There is also a need for structures and incentives to enable faster data sharing of anonymised datasets, and a need to provide similar opportunities to those in high-income countries for clinical trial research in low-resource regions where clinical trial research receives considerably less research funding

Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study

Background: Duchenne muscular dystrophy (DMD) is caused by DMD gene mutations, resulting in absence of functional dystrophin protein. Viltolarsen, an exon 53 skipping therapy, significantly increased dystrophin levels in patients with DMD. Presented here are completed study results of \u3e 4 years of functional outcomes in viltolarsen-treated patients compared to a historical control group (Cooperative International Neuromuscular Research Group Duchenne Natural History Study [CINRG DNHS]). Objective: To evaluate the efficacy and safety of viltolarsen for an additional 192 weeks in boys with DMD. Methods: This phase 2, open-label, 192-week long-term extension (LTE) study (NCT03167255) evaluated the efficacy and safety of viltolarsen in participants aged 4 to \u3c 10 years at baseline with DMD amenable to exon 53 skipping. All 16 participants from the initial 24-week study enrolled into this LTE. Timed function tests were compared to the CINRG DNHS group. All participants received glucocorticoid treatment. The primary efficacy outcome was time to stand from supine (TTSTAND). Secondary efficacy outcomes included additional timed function tests. Safety was continuously assessed. Results: For the primary efficacy outcome (TTSTAND), viltolarsen-treated patients showed stabilization of motor function over the first two years and significant slowing of disease progression over the following two years compared with the CINRG DNHS control group which declined. Viltolarsen was well tolerated, with most reported treatment-emergent adverse events being mild or moderate. No participants discontinued drug during the study. Conclusions: Based on the results of this 4-year LTE, viltolarsen can be an important treatment strategy for DMD patients amenable to exon 53 skipping